6 December 2023
Scientists Plead to Be Heard in Pesticide Debate: Exposure Linked to Risk of Developing Parkinson´s Disease Via Changes in Gut Microbiome
Amsterdam, the Netherlands – While the European Union has just renewed the approval of the use of herbicide glyphosate for another ten years, scientists issue a call to action to reduce or replace the use of agrochemicals.
9 November 2023
Los Angeles, USA – Global independent academic publisher Sage has acquired IOS Press, an independent publisher founded in Amsterdam in 1987 that specializes in health, life, and computer sciences.
21 June 2023
Amsterdam, The Netherlands - Editors-in-Chief Bas Bloem, MD, PhD, and Lorraine Kalia, MD, PhD, proudly announce Journal of Parkinson's Disease (JPD) has been accepted into the Directory of Open Access Journals (DOAJ). Being included in the DOAJ is a significant milestone as it means that JPD meets the rigorous standards of the DOAJ's evaluation process, which assesses the quality, openness, and transparency of open access journals.
23 March 2023
Healthcare professionals recommend adding “hopamine” as a prerequisite for personalized medicine. Based on the personal experiences of Marina Noordegraaf, a commentary published in the Journal of Parkinson’s Disease, proposes that adding “hopamine” to the therapeutic mix can contribute to the empowerment of persons with Parkinson's disease.
14 March 2023
Trichloroethylene (TCE), a chemical used for decaffeinating coffee and dry cleaning clothes, is linked to Parkinson's disease and known to cause cancer, miscarriages, and heart disease. Millions of people are exposed to TCE through contaminated groundwater and indoor air pollution, increasing their risk of developing Parkinson's.
16 December 2022
The Journal of Parkinson’s Disease and its publisher IOS Press are proud to announce the two articles that have won the 2022 Parkinson Prize. The authors of these articles are being recognized for their outstanding contributions to the advancement of Parkinson’s disease (PD) research. Recipients of the award are co-authors Thomas G. Beach, MD, PhD, FRCPC, Banner Sun Health Research Institute, and Charles H. Adler, MD, PhD, FAAN, Mayo Clinic Arizona (basic research article), and Simon Stott, PhD, Cure Parkinson’s (clinical research article).
1 December 2022
Amsterdam, NL – In this special supplement to the Journal of Parkinson’s Disease, “The Immune System in Parkinson’s Disease,” experts highlight the latest research breakthroughs on the links between immune activation and neuroinflammation and Parkinson’s disease (PD) and discuss the challenges and novel therapeutic strategies targeting the immune system with the hope of reducing or reversing neurodegeneration.
18 October 2022
Amsterdam, October 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce that beginning in January 2023, JPD will transition to a Gold Open Access publication. This means that all articles published after that date will be immediately and permanently freely available online for readers to view, download, share, and reuse, and will enable authors to comply more easily with funder and institutional mandates.
17 June 2022
Neurologist Bas Bloem, MD, PhD, FRCPE of Radboud University Medical Center receives this year’s Stevin Prize of the Dutch Research Council (NWO). The Stevin Award is the highest distinction in science for a researcher in the Netherlands who has achieved particular success in the area of knowledge utilization for society. Prof. Bloem is the recipient of this award for the social impact of his research into this common and debilitating disorder.
20 May 2022
The Journal of Parkinson’s Disease is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.
10 May 2022
Although there is a growing trend to involve patients in clinical research, specific guiding principles for engaging individuals with Parkinson’s disease have not been established. The authors of this Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson’s disease studies and recommend how to include patient researchers effectively.
14 April 2022
We share the news that Patrik Brundin, MD, PhD has decided to step down as co-Editor-in-Chief (EIC), of the Journal of Parkinson’s Disease, with immediate effect, following his acceptance of a new position at Roche Pharmaceutical Research and Early Development. As a consequence of his moving away from academia, he now steps down from the journal to prevent any form of conflict of interests.
15 March 2022
The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study in JPD has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.
30 September 2021
Current knowledge about Parkinson’s disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In a position paper published in JPD, MJFF research staff define four major areas of action to reduce health disparities and advance treatments for everyone with PD. It highlights steps the Foundation is taking in these areas, including a new program launched earlier this year.
23 September 2021
After several decades of pre-clinical development, cell- and gene-based therapies for Parkinson’s disease (PD) are now actively being explored. In this JPD special issue on “Repairing the Parkinsonian Brain,” experts highlight some of the current strategies being pursued to restore lost function and replace what is lost in the PD brain, with special emphasis on the challenges associated with translating advanced therapeutic approaches into pioneering clinical trials.
31 August 2021
Results of a new European study published in JPD may help improve clinical practice by shedding light on the lives of people with PD and their carers, re-emphasizing the many challenges they face in everyday life.
30 August 2021
Patients with Parkinson’s disease (PD) are at higher risk for vaccine-preventable respiratory illnesses. However, patients with advanced PD may have less access to vaccinations according to a new study published in the JPD. More than 30% of patients surveyed did not know whether their physicians
20 July 2021
Amsterdam, NL – Well over six million people globally have been diagnosed with Parkinson’s disease (PD), which has an enormous impact on the lives of patients, their families, and caregivers and is incurring mounting costs for society.
29 April 2021
28 April 2021
Amsterdam, NL – Parkinson’s disease (PD) is characterized by slowness of movement and tremors, which often appear asymmetrically in patients.
26 April 2021
Amsterdam, NL – Individuals with Parkinson’s disease (PD) face a wide range of symptoms and challenges.
3 February 2021
Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in JPD, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication.
26 January 2021
Amsterdam, NL – With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD).